JHVEPhoto
- Eli Lilly (LLY) announced on Thursday that retatrutide, its next-gen obesity therapy targeting GIP, GLP-1, and glucagon triple hormone receptors, caused up to 28% weight loss over 80 weeks in a pivotal Phase 3 trial.
- The TRIUMPH-1 was designed to
